Aileron Therapeutics is a clinical stage company discovering and developing novel medicines for the treatment of cancer and for cancer supportive care by targeting high value and historically undruggable intracellular targets using a proprietary platform of stabilized cell-permeating peptides. Our lead product candidate, ALRN-6924, is a first-in-class dual MDM2/MDMX inhibitor that has been tested in hematologic cancers and is currently being evaluated in a Phase 2 clinical trial in combination with Pfizerâs palbociclib (IbranceÂŽ) for the treatment of MDM2-amplified advanced solid cancers, and in an upcoming Phase 1b/2 clinical trial to evaluate ALRN-6924 as a myelopreservative agent to protect against chemotherapy-induced toxicities. Emerging ALRN-6924 clinical and substantial preclinical data support its use across multiple cancer types as a combination therapy with targeted agents, chemotherapies, and immuno-oncology drugs. Aileron Therapeutics is exploring collaboration opportunities regarding ALRN-6924 and for its research in areas such as targeted protein degradation, HIF1-Îą, and the Bcl-2 family of cancer targets. Source
No articles found.
Since Aclaris was founded in 2012, our focus has been innovation to help people wi...
Since Aclaris was founded in 2012, our focus ha...
Freshmynd is developing a breakthrough ADHD supplement for kids backed by 20+ inde...
Freshmynd is developing a breakthrough ADHD sup...
Otonomy is a biopharmaceutical company dedicated to the development of innovative ...
Otonomy is a biopharmaceutical company dedicate...
Cyclacel's founding scientist, Professor Sir David Lane, a globally recognized aut...
Cyclacel's founding scientist, Professor Sir Da...
Hoth Therapeutics is a development stage biopharmaceutical company focused on prop...
Hoth Therapeutics is a development stage biopha...
OncoSec Medical Incorporated is a clinical-stage biotechnology company focused on ...
OncoSec Medical Incorporated is a clinical-stag...
CytoDyn is a publicly traded late stage biotechnology company developing innovativ...
CytoDyn is a publicly traded late stage biotech...
Join the National Investor Network and get the latest information with your interests in mind.